Core Viewpoint - Guangkang Biochemical (300804) has approved the continuation of foreign exchange derivative trading, with a total limit of up to 50 million USD for the next 12 months, starting from September 23 [1] Group 1: Business Operations - The company plans to use its own funds for foreign exchange derivative trading, primarily involving USD, through methods such as forward foreign exchange contracts [1] - The previous authorization for this trading activity is set to expire on September 23, and the new authorization will be effective for 12 months with funds being reusable [1] Group 2: Risk Management - The company acknowledges potential risks associated with market fluctuations and exchange rate volatility, and has established corresponding management measures to mitigate these risks [1] - The trading business is closely related to the company's operations and is expected to enhance financial stability [1] Group 3: Governance and Approval - The proposal has been approved by the board of directors and the audit committee, with no objections from the sponsor [1]
广康生化拟开展不超5000万美元外汇衍生品交易业务